These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 28328954

  • 1. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients.
    Yu MY, Yeo JH, Park JS, Lee CH, Kim GH.
    PLoS One; 2017; 12(3):e0173542. PubMed ID: 28328954
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
    Georgianos PI, Liampas I, Kyriakou A, Vaios V, Raptis V, Savvidis N, Sioulis A, Liakopoulos V, Balaskas EV, Zebekakis PE.
    Int Urol Nephrol; 2017 Dec; 49(12):2217-2221. PubMed ID: 29027620
    [Abstract] [Full Text] [Related]

  • 3. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
    Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, Vallée M, Savoie M, Perreault S, Laurin LP, Pichette V, Lafrance JP.
    Clin J Am Soc Nephrol; 2015 Dec 07; 10(12):2136-42. PubMed ID: 26576619
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety analysis of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on rapid reduction of potassium in moderate to severe hyperkalemia patients with chronic kidney disease without dialysis.
    Fu X, Zhang S, Gao F, Mao N.
    Clin Nephrol; 2024 Oct 07; 102(4):223-231. PubMed ID: 38994592
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of Sodium Polystyrene Sulfonate Dosing Strategies in the Inpatient Management of Hyperkalemia.
    Mistry M, Shea A, Giguère P, Nguyen ML.
    Ann Pharmacother; 2016 Jun 07; 50(6):455-62. PubMed ID: 27048188
    [Abstract] [Full Text] [Related]

  • 6. Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.
    Arnold R, Pianta TJ, Pussell BA, Kirby A, O'Brien K, Sullivan K, Holyday M, Cormack C, Kiernan MC, Krishnan AV.
    Clin J Am Soc Nephrol; 2017 Oct 06; 12(10):1569-1577. PubMed ID: 28893921
    [Abstract] [Full Text] [Related]

  • 7. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia.
    Nakayama Y, Ueda K, Yamagishi SI, Sugiyama M, Yoshida C, Kurokawa Y, Nakamura N, Moriyama T, Kodama G, Minezaki T, Ito S, Nagata A, Taguchi K, Yano J, Kaida Y, Shibatomi K, Fukami K.
    Clin Exp Nephrol; 2018 Feb 06; 22(1):35-44. PubMed ID: 28421299
    [Abstract] [Full Text] [Related]

  • 8. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators.
    JAMA; 2015 Jul 14; 314(2):151-61. PubMed ID: 26172895
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators.
    N Engl J Med; 2015 Jan 15; 372(3):211-21. PubMed ID: 25415805
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of pediatric hyperkalemia with sodium polystyrene sulfonate.
    Lee J, Moffett BS.
    Pediatr Nephrol; 2016 Nov 15; 31(11):2113-7. PubMed ID: 27215929
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency.
    Thompson K, Flynn J, Okamura D, Zhou L.
    J Ren Nutr; 2013 Sep 15; 23(5):333-9. PubMed ID: 23707305
    [Abstract] [Full Text] [Related]

  • 16. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.
    Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS.
    Kidney Int; 2015 Aug 15; 88(2):404-11. PubMed ID: 25651363
    [Abstract] [Full Text] [Related]

  • 17. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.
    Bridgeman MB, Shah M, Foote E.
    Nephrol Dial Transplant; 2019 Dec 01; 34(Suppl 3):iii45-iii50. PubMed ID: 31800078
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study.
    Riccio E, D'Ercole A, Sannino A, Hamzeh S, De Marco O, Capuano I, Buonanno P, Rizzo M, Pisani A.
    J Nephrol; 2024 May 01; 37(4):1077-1084. PubMed ID: 38319545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.